A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(17 sites)
United States
Honor Health, Scottsdale, Arizona Arizona Oncology Associates, Tucson, Arizona Usc Norris Comprehensive Cancer Center, Los Angeles, California Yale University School of Medicine, New Haven, Connecticut D&H Cancer Research Center, Margate, Florida South Florida Gynecology, Tampa, Florida Northwest Cancer Centers, Dyer, Indiana Norton Cancer Institute, Louisville, Kentucky Women's Cancer Care, Covington, Louisiana Pci Nyu Langone Health, New York, New York Albert Einstein College of Medicine Montefiore Medical, New York, New York University Hospitals Seidman Cancer Center, Cleveland, Ohio Oncology Associates of Oregon, Eugene, Oregon Allegheny Singer Research Institute D/B/A Ahn Research Institution, Pittsburgh, Pennsylvania Mary Crowley Cancer Research, Dallas, Texas Texas Oncology- Gulf Coast, The Woodlands, Texas Multicare Institute For Research & Innovation, Tacoma, Washington Last updated October 2025